You can buy or sell MRSN and other stocks, options, ETFs, and crypto commission-free!
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. Read More The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Expected Aug 14, Pre-Market